MPX International Corp.
MPXOF
Other OTC0.00
USD
- -
- -
ISIN
CA55344L1022
CUSIP
55344L102
Return %
Stock
S&P500
1Y
0.00
19.25
3Y
-96.00
65.11
5Y
-99.86
72.21
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- W. Scott Boyes
- Full Time Employees
- 200
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 5255 Yonge Street Toronto ON Canada M2N 6P4
- IPO Date
- Mar 6, 2019
- Website
- mpxinternationalcorp.com
- Similar Companies
- Business
- MPX International Corporation (MPXOF), founded in 2015 and headquartered in Toronto, Ontario, Canada, operates as a multinational diversified cannabis company focused on cultivating, manufacturing, extracting, and marketing cannabinoid-based products for medical and consumer markets across seven countries on five continents, including Canada, Switzerland, South Africa, Malta, Australia, Germany, and Thailand. The company offers a broad portfolio encompassing over 90 medical SKUs such as EU-GMP quality cannabis oils, derivatives, and tablets; more than 60 consumer and wellness SKUs including hemp prerolls, concentrates, extracts via supercritical CO2 and ethanol processes, distillates, nano-emulsions, and custom formulations utilizing nine cannabinoids; and branded products under HOLYWEED, beleaf, SALSUS, MPX labs, Canveda, SPARTAN WELLNESS, HIGH12, STRAIN REE, PENNIES, Kingsway, DAIZE, and alice, complemented by retail operations, e-commerce, and distribution channels targeting regulated medical and adult-use segments. Operations feature vertically integrated facilities from highly automated indoor grows to multi-hectare outdoor farms, GMP-compliant production sites, Swiss extraction labs, and retail outlets emphasizing education and premium experiences. Following its 2020 spin-off from iAnthus Capital Holdings via a $1.6 billion merger that segregated non-U.S. assets, MPX International completed the 2019 acquisition of a GMP-ready pharmaceutical facility in Malta from Alphafarma in partnership with Bortex for local manufacturing support and EU medical cannabis production, alongside the acquisition of HolyWeed as a Swiss premium organic cannabis entity, positioning it for expanded global distribution and innovation in cannabinoid therapeutics.